Elinzanetant

Brand names: Lynkuet · Active ingredient: Elinzanetant

In short: LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

Forms & strengthsCapsules: 60 mg, opaque red, oblong, soft, gelatin capsules, with white printing of "EZN60".
LabelBayer HealthCare Pharmaceuticals Inc.
Label updatedAug 04, 2026

What is Elinzanetant used for?

LYNKUET is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

Elinzanetant dosage

Exclude pregnancy in females of reproductive potential , Warnings and Precautions (5.3), and Use in Specific Populations (8.3)].

Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury [including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP), and serum bilirubin (total and direct)] before initiating treatment with LYNKUET. Do not start LYNKUET if ALT or AST is ≥ 2 times upper limit of normal (ULN) or if the total bilirubin is ≥ 2 times ULN .

The recommended dosage of LYNKUET is 120 mg (two 60 mg capsules) orally once daily at bedtime at about the same time each day. If a dose is missed at bedtime, take the next dose as scheduled on the following day. Do not take two doses on the same day to make up for a missed dose.

Take LYNKUET with or without food. Take LYNKUET with water and swallow capsules whole. Do not cut, crush or chew capsules.

Dosage modifications for concomitant use with specific drugs are provided in Table 1 .

Concomitant Drug | LYNKUET Dosage

Strong CYP3A4 inhibitors and grapefruit (juice) | Avoid concomitant use

Moderate CYP3A4 inhibitors | 60 mg (one capsule) orally once daily at bedtime .

After discontinuation of the moderate CYP3A4 inhibitor (after 3 to 5 half-lives of the inhibitor), LYNKUET should be used at the usual dosage of 120 mg once daily.

Strong and Moderate CYP3A4 inducers | Avoid concomitant use

How to take Elinzanetant — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

CNS Depressant Effect and Daytime Impairment

Advise patients who experience somnolence and other nervous system effects to refrain from driving or engaging in hazardous occupations or activities until the effects have resolved .

Hepatic Transaminase Elevations

Advise patients that bloodwork to evaluate for hepatic functions and injury will be obtained at baseline and three months after initiating therapy.

Advise patients to discontinue LYNKUET immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain). .

Females of Reproductive Potential

Exclude pregnancy in females of reproductive potential prior to initiating LYNKUET. Advise females of reproductive potential to use effective contraception during treatment with LYNKUET and for two weeks after discontinuing treatment and to discontinue LYNKUET if pregnancy is confirmed .

Risk of Seizure

Advise patients about the potential risk of seizure. …

Warnings & precautions

Do not take this medicine if: LYNKUET is contraindicated in pregnancy. Exposure to LYNKUET may cause pregnancy loss or stillbirth when administered during pregnancy .

In the three OASIS trials, nervous system effects (including somnolence, fatigue, vertigo, dizziness and presyncope) occurred in 11.9% of patients on LYNKUET compared to 3.5% on placebo. .

Advise patients about the potential for somnolence and other nervous system effects. Advise patients who experience these effects to refrain from driving or engaging in hazardous occupations or activities until the effects have resolved .

Elevations in serum transaminase (ALT and/or AST) concentrations equal to or greater than three times the ULN occurred in 0.6% of patients receiving LYNKUET and 0.4% of patients receiving placebo up to 12 weeks in three clinical trials. Perform baseline bloodwork (including ALT, AST, alkaline phosphatase, and total and direct bilirubin) prior to initiation of LYNKUET to evaluate for hepatic function and injury. Do not start therapy if serum transaminase concentration is equal to or exceeds two times the ULN or if the total bilirubin is equal to or exceeds two times the ULN. Perform follow-up evaluations of hepatic transaminase concentration 3 months after initiation of therapy.

Advise patients to discontinue LYNKUET immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (new onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain).

Discontinue LYNKUET if transaminase elevations exceed five times the ULN or if transaminase elevations exceed three times the ULN and total bilirubin exceeds two times the ULN.

Exclude alternative causes of hepatic laboratory test elevations.

LYNKUET is contraindicated for use in pregnancy . …

Elinzanetant side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Central Nervous System (CNS) Depressant Effect and Daytime Impairment

Hepatic Transaminase Elevations

Risk of Seizure

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of LYNKUET was evaluated in three randomized, double-blind, placebo-controlled, multicenter clinical trials (OASIS 1, OASIS 2, OASIS 3) in 1420 women. In OASIS 1 and OASIS 2 combined, 793 women received LYNKUET or placebo for 12 weeks. After the first 12 weeks, 341 women randomized to LYNKUET continued to receive LYNKUET for another 14 weeks, with a total treatment duration of up to 26 weeks. In OASIS 1 and OASIS 2 combined, 349 women received placebo for the first 12 weeks and 348 women switched to LYNKUET for the next 14 weeks. In OASIS 3, 627 women received LYNKUET or placebo for up to 52 weeks to evaluate long-term safety .

Common Adverse Reactions

In OASIS 1 and 2 combined, through the first 12 weeks, commonly reported adverse reactions in the LYNKUET group (≥2% and greater than in placebo) were headache, fatigue, gastroesophageal reflux disease, dizziness, nausea, and somnolence.

Similar adverse reactions were seen in OASIS 3. …

Drug interactions

Elinzanetant is primarily metabolized via CYP3A4 enzyme. Table 3 describes drug interactions where concomitant use of another drug affects LYNKUET.

Strong and Moderate CYP3A4 Inhibitors

See www.fda.gov/CYPandTransporterInteractingDrugs for examples of strong and moderate CYP3A4 inhibitors, and CYP3A4 inducers.

Prevention or Management | Strong CYP3A4 Inhibitors and grapefruit (juice): Avoid concomitant use.

Moderate CYP3A4 Inhibitors: Reduce the LYNKUET dosage .

Clinical Effect(s) | Strong and moderate CYP3A4 inhibitors increase elinzanetant exposure, which may increase the risk of LYNKUET-associated adverse reactions .

Strong and Moderate CYP3A4 Inducers

Prevention or Management | Strong and moderate CYP3A4 inducers: Avoid concomitant use.

Clinical Effect(s) | Strong and moderate CYP3A4 inducers decrease elinzanetant exposure, which may reduce the effectiveness of LYNKUET.

CYP3A4 Substrates

Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A4 substrates where minimal concentration changes may lead to serious adverse reactions. See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 substrates.

Elinzanetant is a weak inhibitor of CYP3A4. …

About this medicine

LYNKUET is an NK1 and NK3 receptor antagonist.

The chemical name of elinzanetant is 2-[3,5-bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]pyridin-3-yl}-N,2-dimethylpropanamide having a molecular formula of C33H35F7N4O3 and a molecular weight of 668.7.

The structural formula of elinzanetant is:

Elinzanetant is a white to yellowish powder and is practically insoluble in water and slightly soluble under acidic conditions.

Each LYNKUET (elinzanetant) capsule for oral use contains 60 mg of elinzanetant and the following inactive ingredients: all-rac-α-Tocopherol, caprylocaproyl macrogolglycerides, glycerol monocaprylocaprate, glycerol mono-oleate, and polysorbate 80. The capsule is composed of edible ink, ferric oxide red, ferric oxide yellow, gelatin, sorbitol special-glycerin, and titanium dioxide.

How it works: LYNKUET is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f42884ff-7dff-419c-8a0c-affe2ed73818. Read the full official label on DailyMed.